More eyes had vision of at least 20/150 after bevacizumab treatment.
Outcome of bevacizumab (Avastin) injection in patients with age-related macular degeneration and low visual acuity.
Rita Ehrlich … Ruth Axer-Siegel
Retina (Philadelphia, Pa.) · 2008
Purpose
To study the effect of intravitreal bevacizumab for the treatment of long-standing exudative age-related macular degeneration (AMD) and low visual acuity.
Methods
Forty-seven patients (48 eyes) aged 57 to 90 years with AMD for 5 months or more and visual acuity of 20/150 or less were treated with one or more injections of bevacizumab 1.25 mg/0.05 mL between December 2005 and March 2007.
n = 48 eyes
Results
more treated eyes could see at least 20/150 by follow-up
33.3%
at least 20/150 at the
8.3%
before treatment
More results
Thirty-two eyes were treated previously with photodynamic therapy.
Snellen visual acuity improved from 20/150 to hand movements (mean logMAR 1.34 +/- 0.29) to 20/50 to counting fingers (mean logMar 1.2 +/- 0.42) (P = 0.003, paired t-test).
More results
Visual acuity improved by> or =3 lines in 12 eyes (25%); showed no change in 9 eyes (19%); and deteriorated by > or =3 lines in 4 eyes (8.3%).
Mean central retinal thickness (measured in 22 eyes) decreased from 324 +/- 121 mum to 264 +/- 65 mum (P = 0.02, paired t-test).
“
Conclusion
Patients with chronic exudative AMD and low visual acuity may benefit from intravitreal bevacizumab injections.
